Close X
Attorney Spotlight

What colorful method does Claire Miley use to keep up with the latest healthcare regulations as they relate to proposed transactions? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Securities Law Exchange BlogSecurities Law Exchange blog offers insight on the latest legal and regulatory developments affecting publicly traded companies. It focuses on a wide variety of topics including regulation and reporting updates, public company advisory topics, IPO readiness and exchange updates including IPO announcements, M&A trends and deal news.

Read More >

Presentation Recap: 2014 Health Care Investors Conference

Publications

November 19, 2014

Bass, Berry & Sims PLC and Deloitte co-hosted the fourth annual Health Care Investors Conference designed to connect investors with leaders in the health care industry. We discussed trends in health care investing and heard from management teams and their private equity investors about generating and fostering opportunities to create health care solutions. The conference was intended for managing directors and principals at private equity firms and executive management teams of national health care companies.

Supporting organizations included: the Entrepreneur Center, the Healthcare Private Equity Association, the Nashville Health Care Council and the Nashville Capital Network.

The full presentation deck is provided in the pdf below, and materials referenced during the program are available via the following links:

  • Deloitte M&A Trends report 2014 - Over the past 18 months, merger and acquisition (M&A) activity has accelerated in the U.S. That trend is poised to continue, if not increase, according to the first annual Deloitte M&A Trends report. Of the 2,500 corporate and private equity respondents, 84 percent of corporate executives anticipate a sustained, if not accelerated, pace of M&A activity in the next 24 months. The vast majority of private equity executives (89 percent) are expecting average to high deal activity going forward.
  • The Great Consolidation: The potential for rapid consolidation of health systems - Deloitte models estimate that after consolidation in the next decade, only 50 percent of current health systems will likely remain. Executives should consider defining how their hospitals will survive: Should they acquire? Differentiate? Seek other relationship types? Staying the course is no longer an option.

Click below to download the full presentation.

Download Document - 2014 HCIC Presentation

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.